CONMED Corp.

As of August 1, 2025, CONMED Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -24.87% versus the S&P's 12.22%.

As of June 30, 2025, CONMED Corp. is considered undervalued with a P/E ratio of 21 and an attractive valuation grade, but it has underperformed the S&P 500 with a year-to-date return of -24.87%, raising concerns about its growth prospects.

As of June 27, 2025, CONMED Corp. is in a bearish trend with moderate strength, driven by bearish daily moving averages and monthly MACD, despite some mildly bullish signals from weekly indicators, and has significantly underperformed the S&P 500.

As of June 13, 2025, CONMED Corp. is in a bearish trend with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mixed indicators like the MACD and KST showing mild bullishness on the weekly timeframe.

As of April 30, 2025, CONMED Corp. is fairly valued with a P/E ratio of 21 and an EV to EBITDA of 13.82, but has underperformed the S&P 500 with a year-to-date return of -24.50%, indicating potential challenges in meeting growth expectations despite not being overvalued.

CONMED Corporation is a medical technology company that develops and sells surgical devices for minimally invasive procedures. As of March 2025, it reported net sales of $319 million and a market cap of $1.72 billion.

As of Jun 18, CONMED Corp. has a market capitalization of $1.72 billion, with net sales of $1.31 billion and a net profit of $118.75 million over the latest four quarters. The balance sheet shows shareholder's funds of $962.68 million and total assets of $2.31 billion.